BridgeBio Director Files to Sell $2.3M in Stock via 10b5-1 Plan
BridgeBio Pharma, Inc.
Subscribe to track BBIO
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
BridgeBio Director Files to Sell $2.3M in Stock via 10b5-1 Plan
Company: BridgeBio Pharma, Inc. (BBIO) Form: 144 | Filed: 2025/12/15 Significance: Low
Insider: NEIL KUMAR Title: Officer, Director | Relationship: Director, Officer
Transaction: • Type: Proposed Sale • Shares: 30,011 • Approx. Price: $75.15 • Value: $2,255,327 • Owned After: Not Stated
Key Insight: This proposed sale represents a very small fraction (0.018%) of the company's market cap and is being executed under a pre-scheduled 10b5-1 trading plan, reducing its significance as a market signal.
Market Context: The insider has a history of similar sales under this plan, indicating a routine diversification or liquidity strategy rather than a change in outlook.
Comprehensive Analysis
SEC Filing Analysis: BridgeBio Pharma, Inc.
Executive Summary
- Trading Significance: Low
- Key Takeaway: A Director and Officer at BridgeBio Pharma has filed a notice of proposed sale for approximately $2.3 million worth of common stock under a pre-arranged 10b5-1 trading plan.
- Market Impact: The transaction is of low materiality and is unlikely to have a significant impact on the stock price, given its small size relative to the company's market capitalization and its planned nature.
Company Information
| Field | Value |
|---|---|
| Company | BridgeBio Pharma, Inc. |
| Ticker Symbol | BBIO (Inferred) |
| CIK | 0001743881 |
| Industry | PHARMACEUTICAL PREPARATIONS |
Insider Information
| Field | Value |
|---|---|
| Name | NEIL KUMAR |
| CIK | 0001742485 |
| Title/Position | Officer, Director |
| Relationship | Director, Officer |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 144 |
| Transaction Date | 2025/12/15 (Approx. Sale Date) |
| Transaction Code | Not Applicable |
| Security Type | Common |
| Shares Involved | 30,011 |
| Price Per Share | ~$75.15 |
| Total Value | $2,255,326.65 |
| Shares Owned After | Not Stated |
| Ownership Type | Not Stated |
Financial Impact Assessment
Transaction Materiality
| Metric | Value |
|---|---|
| Transaction Value | $2,255,326.65 |
| % of Market Cap | 0.018% |
| Shares Transacted | 30,011 |
| % of Shares Outstanding | 0.016% |
| Materiality Assessment | Low |
Impact Evaluation
- Market Cap Context: For a company with a market capitalization of $12.79 billion, this $2.3 million sale is negligible.
- Transaction Significance: The sale represents a tiny fraction of both the market capitalization (0.018%) and the total shares outstanding (0.016%), falling far below any threshold for material significance.
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: The sale is small and conducted under a 10b5-1 plan adopted on March 31, 2025. Such planned sales are common for executive compensation and diversification and do not typically reflect a change in the insider's view of the company's future prospects.
Volume & Sentiment
- Expected Volume Impact: Minimal. The number of shares is too small to materially affect daily trading volume.
- Sentiment Indicator: Neutral. The market generally disregards small, planned sales by insiders.
Additional Context
Transaction Notes
- Special Circumstances: This is a notice of a proposed sale under a Rule 10b5-1 trading plan. The filing also discloses a pattern of regular sales by the insider and related trusts over the preceding three months, reinforcing the routine nature of these transactions.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.